Timothy Richardson, PhD
Scientific Director of Molecular Innovation
Timothy Richardson is a Senior Research Professor in the Department of Clinical Pharmacology at Indiana University School of Medicine where his primary responsibilities include leading the Medicinal Chemistry Core of the IUSM-Purdue TREAT-AD (Target Enablement to Accelerate Therapy Development for Alzheimer's Disease) Center.
Prior to his transition to the IU School of Medicine, he was a Research Fellow at Eli Lilly and Company. During his industrial career he contributed to discovery programs that delivered new molecular entities for the treatment of endocrine, musculoskeletal and autoimmune diseases. He led technology platform teams focused on gene regulation, epigenetics and nuclear receptors. He also served as a Group Leader in Discovery Chemistry, a role in which he guided multiple discovery teams that built a portfolio of small molecule therapeutics for the treatment of autoimmune diseases.
Dr. Richardson finished his career at Eli Lilly and Company as a founding member of the RNA Therapeutics Team focused on oligonucleotide-based medicines.
Dr. Richardson joined the IBRI in February 2021 as Scientific Director of Molecular Innovation, where he is applying his academic and industrial experience in collaboration with institute scientists and external research partners to drive translational science that rapidly advances novel therapeutics for unmet medical needs.